Causes and Factors Associated With Outcomes in Community-acquired Sepsis and Severe Sepsis in Northeast Thailand
NCT ID: NCT02217592
Last Updated: 2017-11-01
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
5020 participants
Study Classification
OBSERVATIONAL
Study Start Date
2012-05-20
Study Completion Date
2017-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is an observational study to identify the aetiology and factors associated with outcome of community-acquired sepsis and severe sepsis in Northeast Thailand.
Potential study participants will be adult patients who are presented at the hospital with community-acquired sepsis. Clinical specimens (including blood, urine, sputum and throat swabs) will be collected from each participant on admission for culture, PCR and serological tests, and other laboratory tests, including inflammatory markers and genotyping. Participants' treatment will be closely monitored during the duration of their hospital stay. Blood will be again collected at 72 hours after admission. Participants will be contacted at 28 days after admission to determine clinical outcome by phone interview with standardized script.
There will be a total of 5,020 patients enrolled in this study over 3 years.
Potential study participants will be adult patients who are presented at the hospital with community-acquired sepsis. Clinical specimens (including blood, urine, sputum and throat swabs) will be collected from each participant on admission for culture, PCR and serological tests, and other laboratory tests, including inflammatory markers and genotyping. Participants' treatment will be closely monitored during the duration of their hospital stay. Blood will be again collected at 72 hours after admission. Participants will be contacted at 28 days after admission to determine clinical outcome by phone interview with standardized script.
There will be a total of 5,020 patients enrolled in this study over 3 years.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary objective: To determine the causes of community-acquired sepsis and severe sepsis in NE Thailand.
Secondary Objectives:
1. To define the clinical outcome of community-acquired sepsis and severe sepsis in NE Thailand.
2. To determine factors associated with inflammatory response, organ failure, and mortality in community-acquired sepsis and severe sepsis in NE Thailand, including causes of sepsis, sepsis resuscitation, antimicrobial treatment and genetic factors.
3. To evaluate diagnostic tests for infection in community-acquired sepsis and severe sepsis in NE Thailand.
NOTE: THIS STUDY IS CO-SPONSORED BY
1. University of Oxford
2. University of Washington
Secondary Objectives:
1. To define the clinical outcome of community-acquired sepsis and severe sepsis in NE Thailand.
2. To determine factors associated with inflammatory response, organ failure, and mortality in community-acquired sepsis and severe sepsis in NE Thailand, including causes of sepsis, sepsis resuscitation, antimicrobial treatment and genetic factors.
3. To evaluate diagnostic tests for infection in community-acquired sepsis and severe sepsis in NE Thailand.
NOTE: THIS STUDY IS CO-SPONSORED BY
1. University of Oxford
2. University of Washington
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Sepsis
Severe Sepsis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
CASE_ONLY
Study Time Perspective
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Males and females 18 years old
* Thai nationality
* Required hospitalization as decided by the attending physician
* Documented by attending physician that an infection is the primary cause of illness leading to the hospitalization. These can be infections due to any pathogens (bacteria, viruses, fungi and parasites)
* Presence of any 3 of the following Systemic Inflammatory Response Syndrome (SIRS)
* Fever or hypothermia (Core body temperature defined as \> 38.3 C or \< 36.0 C)
* Tachycardia (heart rate \> 90 beats per minute)
* Tachypnea (respiratory rate \> 20 per minute)
* Arterial hypotension (systolic blood pressure (SBP) \< 90 mmHg, mean arterial pressure (MAP) \< 70 mmHg, or SBP decrease \> 40 mmHg)
* White blood cell (WBC) \> 12,000/µL \< 4000/µL or immature forms \> 10%
* Platelet count \< 100,000/microlitre
* Altered mental status with Glasgow Coma Score (GCS) \< 15
* Hypoxemia (Pulse Oximetry Level \< 95)
* Ileus
* Significant edema or positive fluid balance
* Decreased capillary refill or mottling
* Hyperglycemia (plasma glucose \> 140 mg/dL) in the absence of diabetes
* Plasma C-reactive protein \> 2 SD above the normal value
* Plasma procalcitonin \> 2 SD above the normal value
* Arterial hypoxemia (PaO2 / FIO2 \< 300)
* Acute oliguria (urine output \< 0.5 mL/kg/hr or 45 mmol/L for 2 hours)
* Creatinine increase \> 0.5 mg/dL
* INR \> 1.5 or aPTT \> 60 seconds
* Plasma total bilirubin \> 4 mg/dl or 70 mmol/L
* Hyperlactatemia (\> 1 mmol/L)
* Thai nationality
* Required hospitalization as decided by the attending physician
* Documented by attending physician that an infection is the primary cause of illness leading to the hospitalization. These can be infections due to any pathogens (bacteria, viruses, fungi and parasites)
* Presence of any 3 of the following Systemic Inflammatory Response Syndrome (SIRS)
* Fever or hypothermia (Core body temperature defined as \> 38.3 C or \< 36.0 C)
* Tachycardia (heart rate \> 90 beats per minute)
* Tachypnea (respiratory rate \> 20 per minute)
* Arterial hypotension (systolic blood pressure (SBP) \< 90 mmHg, mean arterial pressure (MAP) \< 70 mmHg, or SBP decrease \> 40 mmHg)
* White blood cell (WBC) \> 12,000/µL \< 4000/µL or immature forms \> 10%
* Platelet count \< 100,000/microlitre
* Altered mental status with Glasgow Coma Score (GCS) \< 15
* Hypoxemia (Pulse Oximetry Level \< 95)
* Ileus
* Significant edema or positive fluid balance
* Decreased capillary refill or mottling
* Hyperglycemia (plasma glucose \> 140 mg/dL) in the absence of diabetes
* Plasma C-reactive protein \> 2 SD above the normal value
* Plasma procalcitonin \> 2 SD above the normal value
* Arterial hypoxemia (PaO2 / FIO2 \< 300)
* Acute oliguria (urine output \< 0.5 mL/kg/hr or 45 mmol/L for 2 hours)
* Creatinine increase \> 0.5 mg/dL
* INR \> 1.5 or aPTT \> 60 seconds
* Plasma total bilirubin \> 4 mg/dl or 70 mmol/L
* Hyperlactatemia (\> 1 mmol/L)
Exclusion Criteria
* Infection is not suspected to be a primary cause of the current illness episode leading to the hospitalization. For example, community-acquired sepsis or severe sepsis is considered to be due to stroke, cardiovascular diseases, acute myocardial infarction, cancer, burn, injury, and trauma
* Hospitalized at this study site for this current episode for more than 24 hours before enrollment
* Hospitalized for this current episode for more than 72 hours at another primary/referring hospital
* Prior to this current episode, the patient was admitted to any hospital within the last 30 days
* Prior to enrolment, it is documented by the attending physician that hospital acquired infection is associated with the cause of sepsis or severe sepsis
* Confirmed diagnosis by any method of an infection as a major cause of illnesses leading to hospitalization. For example, a patient who already has had a definite diagnosis of malarial infection by blood smear
* Clinical diagnosis of any specific disease or any specific syndromes such as acute infective diarrhea, acute pneumonia, acute encephalomyelitis and acute myocarditis
* Suspected of having both infectious and non-infectious diseases and infectious disease is a primary cause of illnesses (primary diagnosis) leading to the hospitalization. For example, acute pneumonia with stroke as an underlying disease, etc
* Patients who are admitted to other hospitals and referred to the study site. For example a referred patient who admit to the first hospital less than 48 hours prior to enrollment
* Hospitalized at this study site for this current episode for more than 24 hours before enrollment
* Hospitalized for this current episode for more than 72 hours at another primary/referring hospital
* Prior to this current episode, the patient was admitted to any hospital within the last 30 days
* Prior to enrolment, it is documented by the attending physician that hospital acquired infection is associated with the cause of sepsis or severe sepsis
* Confirmed diagnosis by any method of an infection as a major cause of illnesses leading to hospitalization. For example, a patient who already has had a definite diagnosis of malarial infection by blood smear
* Clinical diagnosis of any specific disease or any specific syndromes such as acute infective diarrhea, acute pneumonia, acute encephalomyelitis and acute myocarditis
* Suspected of having both infectious and non-infectious diseases and infectious disease is a primary cause of illnesses (primary diagnosis) leading to the hospitalization. For example, acute pneumonia with stroke as an underlying disease, etc
* Patients who are admitted to other hospitals and referred to the study site. For example a referred patient who admit to the first hospital less than 48 hours prior to enrollment
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wellcome Trust
OTHER
Sponsor Role
collaborator
National Institutes of Health (NIH)
NIH
Sponsor Role
collaborator
University of Washington
OTHER
Sponsor Role
collaborator
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Sponsor Role
collaborator
University of Oxford
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dr.Direk Limmathurotsakul
Role: PRINCIPAL_INVESTIGATOR
Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol university, Thailand
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sappasithiprasong Hospital
Ubon Ratchathani, , Thailand
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Thailand
References
Explore related publications, articles, or registry entries linked to this study.
Limmathurotsakul D, Wuthiekanun V, Chantratita N, Wongsuvan G, Amornchai P, Day NP, Peacock SJ. Burkholderia pseudomallei is spatially distributed in soil in northeast Thailand. PLoS Negl Trop Dis. 2010 Jun 1;4(6):e694. doi: 10.1371/journal.pntd.0000694.
Reference Type
BACKGROUND
Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001 Jul;29(7):1303-10. doi: 10.1097/00003246-200107000-00002.
Reference Type
BACKGROUND
Cheng AC, West TE, Limmathurotsakul D, Peacock SJ. Strategies to reduce mortality from bacterial sepsis in adults in developing countries. PLoS Med. 2008 Aug 19;5(8):e175. doi: 10.1371/journal.pmed.0050175.
Reference Type
BACKGROUND
Maitland K, Kiguli S, Opoka RO, Engoru C, Olupot-Olupot P, Akech SO, Nyeko R, Mtove G, Reyburn H, Lang T, Brent B, Evans JA, Tibenderana JK, Crawley J, Russell EC, Levin M, Babiker AG, Gibb DM; FEAST Trial Group. Mortality after fluid bolus in African children with severe infection. N Engl J Med. 2011 Jun 30;364(26):2483-95. doi: 10.1056/NEJMoa1101549. Epub 2011 May 26.
Reference Type
BACKGROUND
Suttinont C, Losuwanaluk K, Niwatayakul K, Hoontrakul S, Intaranongpai W, Silpasakorn S, Suwancharoen D, Panlar P, Saisongkorh W, Rolain JM, Raoult D, Suputtamongkol Y. Causes of acute, undifferentiated, febrile illness in rural Thailand: results of a prospective observational study. Ann Trop Med Parasitol. 2006 Jun;100(4):363-70. doi: 10.1179/136485906X112158.
Reference Type
BACKGROUND
Gasem MH, Wagenaar JF, Goris MG, Adi MS, Isbandrio BB, Hartskeerl RA, Rolain JM, Raoult D, van Gorp EC. Murine typhus and leptospirosis as causes of acute undifferentiated fever, Indonesia. Emerg Infect Dis. 2009 Jun;15(6):975-7. doi: 10.3201/eid1506.081405.
Reference Type
BACKGROUND
Phongmany S, Rolain JM, Phetsouvanh R, Blacksell SD, Soukkhaseum V, Rasachack B, Phiasakha K, Soukkhaseum S, Frichithavong K, Chu V, Keolouangkhot V, Martinez-Aussel B, Chang K, Darasavath C, Rattanavong O, Sisouphone S, Mayxay M, Vidamaly S, Parola P, Thammavong C, Heuangvongsy M, Syhavong B, Raoult D, White NJ, Newton PN. Rickettsial infections and fever, Vientiane, Laos. Emerg Infect Dis. 2006 Feb;12(2):256-62. doi: 10.3201/eid1202.050900.
Reference Type
BACKGROUND
Wijedoru LP, Kumar V, Chanpheaktra N, Chheng K, Smits HL, Pastoor R, Nga TV, Baker S, Wuthiekanun V, Peacock SJ, Putchhat H, Parry CM. Typhoid fever among hospitalized febrile children in Siem Reap, Cambodia. J Trop Pediatr. 2012 Feb;58(1):68-70. doi: 10.1093/tropej/fmr032. Epub 2011 Apr 20.
Reference Type
BACKGROUND
Suputtamongkol Y, Hall AJ, Dance DA, Chaowagul W, Rajchanuvong A, Smith MD, White NJ. The epidemiology of melioidosis in Ubon Ratchatani, northeast Thailand. Int J Epidemiol. 1994 Oct;23(5):1082-90. doi: 10.1093/ije/23.5.1082.
Reference Type
BACKGROUND
Limmathurotsakul D, Wongratanacheewin S, Teerawattanasook N, Wongsuvan G, Chaisuksant S, Chetchotisakd P, Chaowagul W, Day NP, Peacock SJ. Increasing incidence of human melioidosis in Northeast Thailand. Am J Trop Med Hyg. 2010 Jun;82(6):1113-7. doi: 10.4269/ajtmh.2010.10-0038.
Reference Type
BACKGROUND
Fowler VG Jr, Olsen MK, Corey GR, Woods CW, Cabell CH, Reller LB, Cheng AC, Dudley T, Oddone EZ. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med. 2003 Sep 22;163(17):2066-72. doi: 10.1001/archinte.163.17.2066.
Reference Type
BACKGROUND
West TE, Chantratita N, Chierakul W, Limmathurotsakul D, Wuthiekanun V, Myers ND, Emond MJ, Wurfel MM, Hawn TR, Peacock SJ, Skerrett SJ. Impaired TLR5 functionality is associated with survival in melioidosis. J Immunol. 2013 Apr 1;190(7):3373-9. doi: 10.4049/jimmunol.1202974. Epub 2013 Feb 27.
Reference Type
BACKGROUND
Booraphun S, Hantrakun V, Siriboon S, Boonsri C, Poomthong P, Singkaew BO, Wasombat O, Chamnan P, Champunot R, Rudd K, Day NPJ, Dondorp AM, Teparrukkul P, West TE, Limmathurotsakul D. Effectiveness of a sepsis programme in a resource-limited setting: a retrospective analysis of data of a prospective observational study (Ubon-sepsis). BMJ Open. 2021 Feb 18;11(2):e041022. doi: 10.1136/bmjopen-2020-041022.
Reference Type
DERIVED
Wright SW, Lovelace-Macon L, Hantrakun V, Rudd KE, Teparrukkul P, Kosamo S, Liles WC, Limmathurotsakul D, West TE. sTREM-1 predicts mortality in hospitalized patients with infection in a tropical, middle-income country. BMC Med. 2020 Jul 1;18(1):159. doi: 10.1186/s12916-020-01627-5.
Reference Type
DERIVED
Rudd KE, Hantrakun V, Somayaji R, Booraphun S, Boonsri C, Fitzpatrick AL, Day NPJ, Teparrukkul P, Limmathurotsakul D, West TE. Early management of sepsis in medical patients in rural Thailand: a single-center prospective observational study. J Intensive Care. 2019 Dec 2;7:55. doi: 10.1186/s40560-019-0407-z. eCollection 2019.
Reference Type
DERIVED
Hantrakun V, Somayaji R, Teparrukkul P, Boonsri C, Rudd K, Day NPJ, West TE, Limmathurotsakul D. Clinical epidemiology and outcomes of community acquired infection and sepsis among hospitalized patients in a resource limited setting in Northeast Thailand: A prospective observational study (Ubon-sepsis). PLoS One. 2018 Sep 26;13(9):e0204509. doi: 10.1371/journal.pone.0204509. eCollection 2018.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MICRO1206
Identifier Type: -
Identifier Source: org_study_id